Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group

Aminah Jatoi, Shauna Hillman, Philip Stella, Erin Green, Alex Adjei, Suresh Nair, Edith Perez, Bipinkur Amin, Steven E. Schild, Rene Castillo, James R. Jett

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Purpose: To answer the question, "should elderly non-small-cell lung cancer patients be offered elderly-specific trials?" Patients and Methods: The North Central Cancer Treatment Group (NCCTG) performed a pooled analysis of elderly patients who participated in elderly-specific trials (required age ≥ 65 years) and age-unspecified trials (required age ≥ 18 years). Between 1998 and 2000, all NCCTG non-small-cell lung cancer (NSCLC) patients with incurable cancer, age ≥ 65 years, and receiving first-line chemotherapy were included. A total of 118 elderly patients participated in elderly-specific trials, and 108, in age-unspecified trials. Demographics and outcomes were compared based on trial type. Results: The median age of elderly patients in elderly-specific trials was greater: median (range): 73 years (65 to 87) and 70 years (65 to 85), respectively (P < .001), as was the percentage older than 80 years: 17% and 3%, respectively (P = .0008). Median survival times were 232 and 302 days, respectively (P = .08). After adjustment for baseline age, Eastern Cooperative Oncology Group performance score, cancer stage, and body mass index, this survival difference was not statistically significant (hazard ratio = 1.25; P = .16). Grade 3 or worse nonhematologic adverse event rates were greater in age-unspecified trials (81% v 57%, respectively; P < .001), as were grade 3 or worse hematologic events (68% v 10%, respectively; P < .001). Conclusion: Elderly patients in NSCLC elderly-specific trials suffered lower rates of severe adverse events with no statistically significant differences in survival. It seems that elderly-specific trials are providing quality care and helping to define optimal cancer therapy in the elderly, particularly among the "oldest of the old."

Original languageEnglish (US)
Pages (from-to)9113-9119
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number36
DOIs
StatePublished - 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Therapeutics
Survival
Quality of Health Care
Body Mass Index
Demography
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. / Jatoi, Aminah; Hillman, Shauna; Stella, Philip; Green, Erin; Adjei, Alex; Nair, Suresh; Perez, Edith; Amin, Bipinkur; Schild, Steven E.; Castillo, Rene; Jett, James R.

In: Journal of Clinical Oncology, Vol. 23, No. 36, 2005, p. 9113-9119.

Research output: Contribution to journalArticle

Jatoi, Aminah ; Hillman, Shauna ; Stella, Philip ; Green, Erin ; Adjei, Alex ; Nair, Suresh ; Perez, Edith ; Amin, Bipinkur ; Schild, Steven E. ; Castillo, Rene ; Jett, James R. / Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 36. pp. 9113-9119.
@article{7f83970ca1c44fc0bca8a64ed0b61938,
title = "Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group",
abstract = "Purpose: To answer the question, {"}should elderly non-small-cell lung cancer patients be offered elderly-specific trials?{"} Patients and Methods: The North Central Cancer Treatment Group (NCCTG) performed a pooled analysis of elderly patients who participated in elderly-specific trials (required age ≥ 65 years) and age-unspecified trials (required age ≥ 18 years). Between 1998 and 2000, all NCCTG non-small-cell lung cancer (NSCLC) patients with incurable cancer, age ≥ 65 years, and receiving first-line chemotherapy were included. A total of 118 elderly patients participated in elderly-specific trials, and 108, in age-unspecified trials. Demographics and outcomes were compared based on trial type. Results: The median age of elderly patients in elderly-specific trials was greater: median (range): 73 years (65 to 87) and 70 years (65 to 85), respectively (P < .001), as was the percentage older than 80 years: 17{\%} and 3{\%}, respectively (P = .0008). Median survival times were 232 and 302 days, respectively (P = .08). After adjustment for baseline age, Eastern Cooperative Oncology Group performance score, cancer stage, and body mass index, this survival difference was not statistically significant (hazard ratio = 1.25; P = .16). Grade 3 or worse nonhematologic adverse event rates were greater in age-unspecified trials (81{\%} v 57{\%}, respectively; P < .001), as were grade 3 or worse hematologic events (68{\%} v 10{\%}, respectively; P < .001). Conclusion: Elderly patients in NSCLC elderly-specific trials suffered lower rates of severe adverse events with no statistically significant differences in survival. It seems that elderly-specific trials are providing quality care and helping to define optimal cancer therapy in the elderly, particularly among the {"}oldest of the old.{"}",
author = "Aminah Jatoi and Shauna Hillman and Philip Stella and Erin Green and Alex Adjei and Suresh Nair and Edith Perez and Bipinkur Amin and Schild, {Steven E.} and Rene Castillo and Jett, {James R.}",
year = "2005",
doi = "10.1200/JCO.2005.03.7465",
language = "English (US)",
volume = "23",
pages = "9113--9119",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group

AU - Jatoi, Aminah

AU - Hillman, Shauna

AU - Stella, Philip

AU - Green, Erin

AU - Adjei, Alex

AU - Nair, Suresh

AU - Perez, Edith

AU - Amin, Bipinkur

AU - Schild, Steven E.

AU - Castillo, Rene

AU - Jett, James R.

PY - 2005

Y1 - 2005

N2 - Purpose: To answer the question, "should elderly non-small-cell lung cancer patients be offered elderly-specific trials?" Patients and Methods: The North Central Cancer Treatment Group (NCCTG) performed a pooled analysis of elderly patients who participated in elderly-specific trials (required age ≥ 65 years) and age-unspecified trials (required age ≥ 18 years). Between 1998 and 2000, all NCCTG non-small-cell lung cancer (NSCLC) patients with incurable cancer, age ≥ 65 years, and receiving first-line chemotherapy were included. A total of 118 elderly patients participated in elderly-specific trials, and 108, in age-unspecified trials. Demographics and outcomes were compared based on trial type. Results: The median age of elderly patients in elderly-specific trials was greater: median (range): 73 years (65 to 87) and 70 years (65 to 85), respectively (P < .001), as was the percentage older than 80 years: 17% and 3%, respectively (P = .0008). Median survival times were 232 and 302 days, respectively (P = .08). After adjustment for baseline age, Eastern Cooperative Oncology Group performance score, cancer stage, and body mass index, this survival difference was not statistically significant (hazard ratio = 1.25; P = .16). Grade 3 or worse nonhematologic adverse event rates were greater in age-unspecified trials (81% v 57%, respectively; P < .001), as were grade 3 or worse hematologic events (68% v 10%, respectively; P < .001). Conclusion: Elderly patients in NSCLC elderly-specific trials suffered lower rates of severe adverse events with no statistically significant differences in survival. It seems that elderly-specific trials are providing quality care and helping to define optimal cancer therapy in the elderly, particularly among the "oldest of the old."

AB - Purpose: To answer the question, "should elderly non-small-cell lung cancer patients be offered elderly-specific trials?" Patients and Methods: The North Central Cancer Treatment Group (NCCTG) performed a pooled analysis of elderly patients who participated in elderly-specific trials (required age ≥ 65 years) and age-unspecified trials (required age ≥ 18 years). Between 1998 and 2000, all NCCTG non-small-cell lung cancer (NSCLC) patients with incurable cancer, age ≥ 65 years, and receiving first-line chemotherapy were included. A total of 118 elderly patients participated in elderly-specific trials, and 108, in age-unspecified trials. Demographics and outcomes were compared based on trial type. Results: The median age of elderly patients in elderly-specific trials was greater: median (range): 73 years (65 to 87) and 70 years (65 to 85), respectively (P < .001), as was the percentage older than 80 years: 17% and 3%, respectively (P = .0008). Median survival times were 232 and 302 days, respectively (P = .08). After adjustment for baseline age, Eastern Cooperative Oncology Group performance score, cancer stage, and body mass index, this survival difference was not statistically significant (hazard ratio = 1.25; P = .16). Grade 3 or worse nonhematologic adverse event rates were greater in age-unspecified trials (81% v 57%, respectively; P < .001), as were grade 3 or worse hematologic events (68% v 10%, respectively; P < .001). Conclusion: Elderly patients in NSCLC elderly-specific trials suffered lower rates of severe adverse events with no statistically significant differences in survival. It seems that elderly-specific trials are providing quality care and helping to define optimal cancer therapy in the elderly, particularly among the "oldest of the old."

UR - http://www.scopus.com/inward/record.url?scp=33644825221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644825221&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.7465

DO - 10.1200/JCO.2005.03.7465

M3 - Article

VL - 23

SP - 9113

EP - 9119

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -